Gerresheimer to spin off moulded glass business
Gerresheimer had been undertaking a “strategic review” of the unit since 2024.
GERMANY – Gerresheimer, a leading provider of packaging solutions for the pharmaceutical, biotech, and cosmetic industries, has announced the spin-off of its moulded glass business into a standalone entity.
According to a company statement, this decision follows an extensive strategic review aimed at optimizing growth and enhancing competitive positioning.
The company plans to initiate a sales process for the newly independent unit, with further details to be shared at its Capital Markets Day on October 15, 2025.
The moulded glass division, bolstered by the 2024 acquisition of Bormioli Pharma, operates eight production facilities across the Americas, Europe, and Asia.
In a statement, Gerresheimer reported that the unit generated approximately USD 850.4 million in revenue in 2024, achieving an adjusted EBITDA margin of around 20%.
The division offers a diverse portfolio of glass packaging solutions, including bottles, jars, and containers, serving the pharmaceutical, cosmetic, and food and beverage sectors.
“We see the best growth opportunities for our newly formed Moulded Glass Powerhouse outside the Gerresheimer Group,” said Dietmar Siemssen, CEO of Gerresheimer.
“As part of our strategic transformation, Gerresheimer will focus even stronger on the portfolio of systems and solutions for the pharma and biotech industry.”
The acquisition of Bormioli Pharma has significantly expanded Gerresheimer’s offerings, incorporating primary packaging and dosing systems for pharmaceuticals while opening avenues for high-value plastic solutions.
Meanwhile, Gerresheimer has recently invested heavily in eco-friendly infrastructure.
Over the past two years, the company allocated USD 108.5 million to upgrade its Lohr am Main facility in Germany with an energy-efficient oxy-hybrid furnace, reducing its environmental footprint.
Additionally, in December 2024, Gerresheimer unveiled a new syringe production hall in Skopje, North Macedonia, backed by a USD 108.5 million investment, further strengthening its pharma-focused portfolio.
Meanwhile, Hans-Norbert Topp, an experienced industry leader, has been appointed to head the moulded glass business unit.
His expertise in integration and transformation processes is expected to drive the unit’s transition into a standalone entity, ensuring its competitiveness in global markets.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
